Can I switch from Ozempic to Mounjaro?

Yes. Many providers help patients switch if they've plateaued on semaglutide. You'd typically start tirzepatide at the lowest dose even if you were on a higher semaglutide dose.

Tirzepatide vs Semaglutide: Which GLP-1 Is More Effective?

Key takeaways

Weight loss: Tirzepatide produces ~20% body weight loss vs ~14% for semaglutide in trials
Mechanism: Tirzepatide targets two receptors (GIP + GLP-1); semaglutide targets one (GLP-1)
Side effects: Similar for both medications
Track record: Semaglutide has longer safety data and proven heart benefits
Cost: Similar ($1,000-1,100/month brand, $200-600 compounded)

The quick answer

Tirzepatide (Mounjaro, Zepbound) produces more weight loss than semaglutide (Ozempic, Wegovy). In head-to-head trials, patients on tirzepatide lost 20.2% of their body weight compared to 13.7% on semaglutide.

That’s a real difference. For someone weighing 220 pounds, tirzepatide means losing about 44 pounds versus 30 pounds on semaglutide.

But semaglutide has been around longer, with more safety data and proven benefits for heart disease. Tirzepatide may catch up on the cardiovascular data, but it’s not there yet.

Head-to-head trial results

The SURMOUNT-5 trial compared tirzepatide and semaglutide directly in adults with obesity. This is the clearest comparison we have.

Results at 72 weeks

Outcome	Tirzepatide (15mg)	Semaglutide (2.4mg)
Average weight loss	20.2% Winner	13.7%
Weight lost (220 lb person)	44 lbs	30 lbs
Patients losing 10%+	85%	73%
Patients losing 20%+	57%	28%

Tirzepatide had roughly double the number of patients reaching 20% weight loss. That’s a meaningful difference for people with a lot to lose.

Real-world data backs this up. A 2026 retrospective study of US patients found tirzepatide produced 11.2% weight loss at 6 months versus 8.8% for semaglutide. The effect holds outside clinical trials.

How they work differently

Semaglutide (Ozempic, Wegovy)

→ Mimics GLP-1, a gut hormone that signals fullness
→ Slows stomach emptying
→ Reduces appetite
→ One mechanism of action

Tirzepatide (Mounjaro, Zepbound)

→ Mimics both GLP-1 and GIP
→ Same stomach-slowing and appetite effects
→ GIP may improve fat and blood sugar handling
→ Dual mechanism of action

The dual mechanism is likely why tirzepatide works better. Targeting two receptors instead of one produces stronger effects.

Weight loss comparison by timepoint

Timepoint	Tirzepatide	Semaglutide
3 months	7-9%	5-7%
6 months	12-15%	8-11%
12 months	18-22%	13-15%

For a 200 lb person, that’s roughly 36-44 lbs lost on tirzepatide at 12 months versus 26-30 lbs on semaglutide.

Side effects comparison

Both medications cause similar gastrointestinal side effects, especially during the first few months:

Side Effect	Tirzepatide	Semaglutide
Nausea	20-30%	20-30%
Diarrhea	15-20%	15-20%
Constipation	10-15%	10-15%
Vomiting	10-15%	10-15%
Injection site reaction	5%	5%

The SURPASS-2 trial found slightly lower nausea rates with tirzepatide at equivalent doses, but the difference was small enough that it shouldn’t drive your decision.

Serious side effects are similar and rare for both: pancreatitis, gallbladder problems, and thyroid tumors (boxed warning based on animal studies).

Cost comparison

Option	Tirzepatide	Semaglutide
Brand (without insurance)	$1,000-1,100/mo	$900-1,400/mo
Brand (with insurance)	$25-500/mo	$25-500/mo
Compounded	$300-600/mo	$200-500/mo

Compounded tirzepatide typically costs $50-150 more per month than compounded semaglutide because the compound is newer and less widely available.

Which should you choose?

Choose tirzepatide if:

→ Maximum weight loss is your priority
→ You have a lot to lose (BMI 35+)
→ Semaglutide hasn’t worked well for you
→ You don’t have existing heart disease concerns

Choose semaglutide if:

→ You want the medication with the longest track record
→ You have heart disease or high cardiovascular risk
→ Cost is a concern (compounded is cheaper)
→ You’re already doing well on it

The honest answer: If weight loss is your main goal and cost isn’t an issue, tirzepatide produces better results. If you’re more cautious about newer medications or have heart health concerns, semaglutide’s longer track record is reassuring.

Some people start with semaglutide and switch to tirzepatide if they plateau. That’s a reasonable approach.

Find a GLP-1 provider

Compare telehealth providers offering both medications.

See provider reviews →

Frequently asked questions

Yes. Tirzepatide produces about 45% more weight loss than semaglutide in head-to-head trials (20% vs 14% body weight).

Yes. Many providers help patients switch if they’ve plateaued on semaglutide or want better results. You’d typically start tirzepatide at the lowest dose even if you were on a higher semaglutide dose.

Tirzepatide targets two gut hormone receptors (GIP and GLP-1) instead of one. This dual mechanism produces stronger appetite suppression and metabolic effects.

Coverage varies. Most insurers cover Ozempic and Mounjaro for diabetes with prior authorization. Coverage for weight loss (Wegovy, Zepbound) is less consistent.

They’re similar. The SURPASS-2 trial showed tirzepatide caused slightly less nausea, but the difference isn’t large enough to make side effects a deciding factor.

The bottom line

Tirzepatide beats semaglutide for weight loss. The clinical data is clear on that. But semaglutide isn’t far behind, costs a bit less, and has more long-term safety data. Either one can produce significant results. The best choice depends on your goals, health history, and what your insurance covers.

References

Aronne LJ, et al. Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-5). New England Journal of Medicine. 2024.
Rodriguez PJ, et al. Comparative effectiveness of tirzepatide and semaglutide for obesity management. Journal of Endocrinological Investigation. 2026.
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
Eli Lilly. Mounjaro Prescribing Information. 2024.
Novo Nordisk. Ozempic Prescribing Information. 2024.

Our commitment to accuracy: This article cites peer-reviewed clinical trials and was reviewed by a board-certified physician. Read our editorial policy.